Member Info for Brighty1

Exactly right. Those 5p a share predictions are very modest. This is a huge global market. Don't forget what happened at UPL and POS. They both climbed over x 10 this year on positive sentiment...

Good luck, Brighty

Here is yet another great example of why we are invested in Sareum. When the licencing pay day comes it will be big....

https://www.jpmorgan.com/content/dam/jpm/commercial-banking/insights/life-sciences/jpmorgan-chase-q3-2023-biopharma-final-ada_v2.pdf

Summary and pertinent to SRA 737 and SDC 1801/1802:

* According to JP Morgan's Q3 2023 Biopharma Licensing and Venture Report (just published) there were a total of 113 licensing deals signed in our sector in the third quarter of 2023 ranging from early stage programmes through to P2/3 clinical trials.

* $1.2 billion was paid in total upfront cash and equity in Q3 in licencing deal payments (Q2 1.3 billion)

* For early stage programmes (e.g. 737 and 1801/1802) the average upfront payment was $47 million to date in 2023, up from $40 million in full-year 2022.

In a nutshell, this is more ammo for Stephen Parker to pick up the phone to Professor Kristian Helin, CEO, at the Institute of Cancer Research and Robert James and Ian Miscampbell at Sixth Element / CPF and lobby and persuade them to get a deal over the line for SRA737. It's in everyone's interests....

Good luck, Brighty

Here's some additional data for all HEMO shareholders to get excited about.

* According to JP Morgan's Q3 2023 Biopharma Licensing and Venture Report (just published) there were a total of 113 licensing deals signed in our sector in the third quarter of 2023 ranging from early stage programmes through to P2/3 clinical trials.

* $1.2 billion was paid in total upfront cash and equity in Q3 in licencing deal payments (Q2 1.3 billion)

* In the early stage space Hemo operates in the average upfront payment was $47 million to date in 2023, up from $40 million in full-year 2022. Hopefully, this is where Prevail Partners will be helping HEMO in attracting a similar size licencing deal.

In summary, the significant amounts paid in licencing deals in our sector is another compelling reason to be invested in HEMO.....

Good luck, Brighty

AimHigherStill: your "wake me up at 5p" slogan needs revising to "Wake Me Up at 50p"......

Good luck, Brighty

Exactly. The daily fluctuations in the GST share price are almost irrelevant in the bigger scheme of things. Jack Bai, Tone Goh, Shayne Tan and Galvin Bai are building something special here from a very low MCAP. This could seriously rocket very soon and could replicate the ARB, GGP, UPL, TPST, NCYT, SAR, POS mega multi-bagger rises we have all seen over recent years....

Good luck, Brighty

Yes, GST is just getting started. Don't forget what happened at UPL and POS. They both climbed over x 10 this year on positive sentiment...

Good luck, Brighty

The 5p a share predictions are modest. 50P a share in the medium to long term is not unreasonable, as I've outlined before. This is a huge global market....

Good luck, Brighty

This has ARB written all over it. It went from 5p to over 250p….

Good luck, Brighty

Exactly and we know what happened with ARB. It went from 5p to 250p+ (& over 300p intra-day) in a short few months. Many on here will remember the ARB share price being 20p on Christmas Eve in 2020. Over the Christmas and New Year break it rose in just a few trading sessions to 145p by January 8th 2021....

Good luck, Brighty

Yes, agreed regarding x 10 multibag from here in the short term. Don't forget what happened at UPL and POS. They both climbed over x 10 this year on positive sentiment. 50p a share is where I think this is heading in due course....

Good luck, Brighty

It won't be too long before the UK / FCA will be embracing the NEO bank model. It has to when you bear in mind that NEO banking has a global market size of 72.47 Billion (2022 figures) already. That is a pretty compelling investment strategy. It's why I'm invested in GST as in due course the share price is going to be many times higher than today.

The 5p a share predictions are modest. 50P a share in the medium to long term is not unreasonable, as I've outlined before. This is a huge global market....

Good luck, Brighty

Exactly Barry. Looks like a possible Greatland / Sareum / Argo style leap could be coming here. You only need to see what’s also happened recently at OBD up 300+% in 1 month, POS up 800+% in 1 month, ORCA up 450+% in one month and Tempest up 3900% in October (yes x 39) to get a taster of what could happen here….

Good luck, Brighty

ARB went from roughly 20p on Christmas Eve 2020 to 145p on 8 2021. Over 12 months it went from 5p to over 250p….

Good luck, Brighty

Yes, $ 4.84B in trading volume on the GS20 Exchange over the last 24 hours. (Tether being the most popular stablecoin on GS20 Exchange). The magnitude of this will start to filter through in the coming days and weeks.

Background for newbies:

* The GS20 Exchange cryptocurrency exchange recorded $ 4.88B in trading volume over the last 24 hours. BTC/USDT is currently the most active trading pair on GS20 Exchange, and saw $ 2.13B in trading volume in the last 24 hours. The biggest gainer on GS20 Exchange today is TRX/EUR, which increased by 4.65% on the day. The worst performing pair on GS20 Exchange is currently XRP/USDT, which saw a -6.28% drop. On GS20 Exchange, you can currently trade 11 trading pairs across 2 markets.

Daily fluctuations in the GST share price are almost irrelevant in the bigger scheme of things. This could rocket very soon. Many on here are predicting another ARB or GGP style multi-bagger....

Good luck, Brighty

NEO banking is the future alongside Crypto. GST could certainly be an ARB, GGP, UPL, TPST, POS mega multi-bagger. All the signs are here for a huge rise. You only have to see what's happened with UPL and POS. They both climbed over x 10 this year before dropping back a bit. Then there's TPST which rose by x39 last month. It's pulled back but is still up over x18....

Good luck, Brighty

A reminder for all Sareum shareholders to keep your eyes fixed on the patent expiry dates, such as:

* Merck MSD’s Keytruda 2029

* Johnson & Johnson’s Stelara 2026

* Bristol Myers Squibb's Revlimid, Eliquis and Opdivoand from 2026

* Takeda's Entyvio’s patent expiration of 2026 etc

i.e. Patents expiring in the next 3-5 years in the pharma sector are worth billions. Plus a reminder that it’s abundantly clear that the Sareum science works. e.g. We know that in 4 combo trials with Adavosertib, Keytruda, Gemcitabine and Dexamethasone that the data has been very very encouraging.

* WEE1 / Adavosertib (AZ) for the treatment of selected TP53 mutated cancers.

* Keytruda (Merck) with 100% regression of tumours after 21 days

* Gemcitabine (Eli Lilly) with positive safety and efficacy in anogenital cancer

Plus we know that in combo with dexamethasone - and I quote - “The Sareum compound as a single agent was well tolerated and there was no change in tolerability when combined with dexamethasone”, Tim Mitchell & Stephen Parker.

Have a great weekend.

Good luck, Brighty

A reminder that HEMO went up x 8 from 1.8p up to 15.2p three years ago, see trading data below. i.e. Over 800% in just one week. Anything is possible with pharma shares. If the news is as good as many on here are predicting it could easily happen here again. A x 8 from 2.50p today would be 20p a share. Therefore those 10p-15p predictions are looking encouraging...

Date Open High Low Close

Apr 30, 2020 7.50 11.25 7.20 10.00

Apr 29, 2020 10.90 15.2475 6.70 8.00

Apr 28, 2020 5.00 10.80 4.70 10.20

Apr 27, 2020 2.265 4.50 2.265 4.35

Apr 24, 2020 2.07 2.3949 1.9663 2.275

Apr 23, 2020 2.2111 2.2475 1.92 2.025

Apr 22, 2020 1.837 2.70 1.71 2.225

Good luck, Brighty

Exactly. Prevail Partners have been encouraged by what they have seen at HEMO. Hence why they paid a 200% premium of 6p+ a share for a piece of the forthcoming HEMO action.....

Good luck, Brighty

Here we are. From Bloomberg re x39 rise last month for TPST. It happens ......

https://www.bloomberg.com/news/articles/2023-10-13/near-4-000-surge-catapults-one-tiny-biotech-firm-to-record-week

Good luck, Brighty

Agreed. This certainly has an ARB, GGP, UPL, TPST, POS multi-bag feel to it. All the vibes are here for a big gain. Don't forget what happened at UPL and POS. They both climbed over x 10 this year before dropping back a bit. Then there's TPST which rose by x39 last month. It's pulled back but is still up over x18. Its market cap, by the way, surged 127 million in 1 week. i.e. Gains like this do happen. It's why I am invested in GST....

Good luck, Brighty